瑞博生物于2007年由资深海归博士和国内专家团队创立，致力于自主知识产权的小核酸药物研发，以及在全球范围内开展临床项目研发及商业化
Location: China
Investors 2
| Date | Name | Website |
| 13.05.2024 | Pan Lin In... | panlincap.... |
| - | SDIC Fund ... | sdicfund.c... |
Mentions in press and media 11
| Date | Title | Description |
| 31.08.2026 | Gothenburg looks to strengthen ties with Germany | Gothenburg looks to strengthen ties with Germany Mon, Aug 31, 2026 14:06 CET Report this content Germany has long played a key role in Gothenburg's international business landscape. This autumn, Business Region Göteborg will be at five majo... |
| 22.07.2026 | Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease | SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical I... |
| 02.07.2026 | Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH | SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pha... |
| 28.05.2026 | Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease | SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to t... |
| 12.05.2026 | Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI | SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.... |
| 12.05.2026 | Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development | SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreeme... |
| 06.05.2026 | Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH) | SUZHOU, China and MÖLNDAL, Sweden, May 6, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third ke... |
| 11.02.2026 | Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entere... |
| 09.01.2026 | Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange | HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main ... |
| 24.10.2025 | Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection | BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to R... |
Show more